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ABSTRACT
Objectives Synovial ﬂuid glutamate concentrations
increase in arthritis. Activation of kainate (KA) and α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) glutamate receptors (GluRs) increase interleukin-
6 (IL-6) release and cause arthritic pain, respectively. We
hypothesised that AMPA and KA GluRs are expressed in
human arthritis, and that intra-articular NBQX (AMPA/
KA GluR antagonist) prevents pain and pathology in
antigen-induced arthritis (AIA).
Methods GluR immunohistochemistry was related to
synovial inﬂammation and degradation in osteoarthritis
(OA) and rheumatoid arthritis (RA). A single intra-
articular NBQX injection was given at induction, and
knee swelling and gait of AIA and AIA+NBQX rats
compared over 21 days, before imaging, RT-qPCR,
histology and immunohistochemistry of joints. Effects of
NBQX on human primary osteoblast (HOB) activity were
determined.
Results AMPAR2 and KA1 immunolocalised to
remodelling bone, cartilage and synovial cells in human
OA and RA, and rat AIA. All arthritic tissues showed
degradation and synovial inﬂammation. NBQX reduced
GluR abundance, knee swelling (p<0.001, days 1–21),
gait abnormalities (days 1–2), end-stage joint destruction
(p<0.001), synovial inﬂammation (p<0.001), and
messenger RNA expression of meniscal IL-6 (p<0.05)
and whole joint cathepsin K (p<0.01). X-ray and MRI
revealed fewer cartilage and bone erosions, and less
inﬂammation after NBQX treatment. NBQX reduced HOB
number and prevented mineralisation.
Conclusions AMPA/KA GluRs are expressed in human
OA and RA, and in AIA, where a single intra-articular
injection of NBQX reduced swelling by 33%, and
inﬂammation and degeneration scores by 34% and
27%, respectively, exceeding the efﬁcacy of approved
drugs in the same model. AMPA/KA GluR antagonists
represent a potential treatment for arthritis.
INTRODUCTION
Inﬂammation underlies pathology in osteoarthritis
(OA)1–3 and rheumatoid arthritis (RA).4 Non-
steroidal anti-inﬂammatory drugs, corticosteroids
and anti-cytokine treatments that have revolutio-
nised RA treatment4 also relieve OA symptoms
with varying success.5–9 Here, we investigate
whether glutamate receptor (GluR) antagonists rep-
resent a new treatment targeting inﬂammatory
stages of arthritis.
Synovial ﬂuid (SF) glutamate concentrations
increase 52-fold in RA (326 mM) and 42-fold in OA
(266 mM)10 and in arthritis animal models.11 12 In
RA, high SF glutamate correlates with increased
inﬂammatory mediators.13 14 Glutamate is now
known to signal in various ‘non-excitable’ cells,15–17
being released by nerves, macrophages, lympho-
cytes, synoviocytes, osteoblasts, osteoclasts and
chondrocytes,11 14 18 19 and acting on ionotropic
glutamate receptors (iGluRs) and metabotropic
GluRs in multiple joint cell types.18 20 21 GluRs
regulate peripheral pain,22 cytokine and matrix
metalloproteinase (MMP) release,20 synoviocyte
proliferation23 24 and immune responses.21
Therefore, GluR antagonists represent potential
drugs with multimodal activity against arthritis
symptoms.
Intra-articular injections of iGluR antagonists have
been shown to inhibit pain for 24 h in murine
carrageenan-induced arthritis (MK801, NBQX),25
suppress inﬂammatory pain for 24 h in arthritic mice
(GYKI 52466, 1-NAS)26 and alleviate allodynia over
7 days in complete Freund’s adjuvant (CFA)-induced
arthritis when combined with a substance P receptor
antagonist and dexamethasone.27 Of two studies
investigating the effects of GluR antagonists on arth-
ritic pathology, one showed that a single
intra-articular treatment targeting all iGluRs did not
affect cartilage erosion in CFA arthritis,27 and the
other revealed that continual systemic administration
of memantine (N-methyl-D-aspartate receptor
(NMDAR) antagonist) alleviated synovitis and joint
destruction in collagen-induced arthritis (CIA).21
Long-term effects of single treatments of GluR
antagonists on arthritic pain, inﬂammation and path-
ology are unknown, and no studies have investigated
the pathological effects of α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)/kainate
(KA) GluR antagonists.
Since SF glutamate concentrations increase
immediately after arthritis induction,11 AMPA
GluRs mediate arthritic pain26 and KA GluR activa-
tion causes interleukin-6 (IL-6) release,20 a critical
mediator of arthritic joint destruction,28 we
hypothesised that early intra-articular intervention
with NBQX (AMPA/KA GluR antagonist) would
reduce pain, inﬂammation and pathology in inﬂam-
matory arthritis. The antigen-induced arthritis
(AIA) rat model was used as it shares pathological
features of human inﬂammatory arthritis,29 has
deﬁned IL-6 release proﬁles29 and does not require
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analgesia. NBQX was administered at arthritis induction, prior
to peak IL-6 concentrations, and gait, knee swelling, synovial
inﬂammation, GluR expression and joint degeneration deter-
mined. To assess relevance to inﬂammatory processes in human
arthritis, we investigated AMPA and KA GluR expression in
human RA and OA knees.
METHODS
Patients
Matched synovium and medial tibial plateaux (MTP) were
obtained (informed consent, Ref: 10/MRE0928) from randomly
selected patients undergoing total knee replacement for OA
(two women, one man) or RA (one man).
Animals
Procedures were performed according to Home Ofﬁce guide-
lines on male Lewis rats (∼200 g, Harlan, UK) housed in groups
of three (12 h light–dark cycles, ad libitum food and water).
Arthritis and treatments
After two subcutaneous injections of methylated bovine serum
albumin (mBSA; 0.5 mg/mL; Sigma) emulsiﬁed with an equal
volume of CFA (0.25 mg Mycobacterium tuberculosis, Sigma)
7 days apart, AIA was induced29 by a single intra-articular injec-
tion (in 50 mL saline) into the right knee 14 days later (day 0).
Induction was either with 0.5 mg mBSA alone (15 rats, AIA) or
0.5 mg mBSA+2.5 mM NBQX (Tocris) (15 rats, AIA
+NBQX).25 The main comparisons in this intervention study
were between AIA and AIA+NBQX rats, but naive rats (n=6)
revealed effects of AIA. All measurements were taken at days 0
(baseline), 1, 2, 3, 4, 7, 9, 14 and 21, unless stated.
Sample processing
Human synovium, MTP and whole rat knees were ﬁxed (2 days,
10% neutral buffered formalin, Sigma), decalciﬁed (4°C, 10%
EDTA, Fisher Scientiﬁc), parafﬁn embedded and coronally sec-
tioned (6 mm).
Histology
Consecutive sections from all human samples and nine AIA,
nine AIA+NBQX and three naive rats (day 21) were stained
with H&E (synovial inﬂammation), toluidine blue/safranin-O
(cartilage and bone) or retained for immunohistochemistry.
Two independent observers blinded to treatment used pub-
lished scoring systems to assess human OA30 and rat31 synovial
inﬂammation and human MTP degradation,32 and a modiﬁed
Mankin score for rat knee degradation (see online supplemen-
tary tables S1–S4). Average scores of two sections ∼500 mm
apart are presented for rats.
Immunohistochemistry and TRAP staining
GluRs were immunolocalised in sequential sections from human
synovium, human MTP and rat knees (numbers as above) using
antibodies to KA receptor-1 and AMPA receptor-2 (AMPAR2)
(anti-KA1, anti-iGluR2; Abcam, see online supplementary
methods). Sections underwent antigen retrieval (1 mg/mL
trypsin, Sigma), peroxidase blocking, overnight incubation (4°C)
with primary antibody and detection (Vectastain Elite ABC kit,
nickel enhanced diaminobenzidine, Vector Laboratories). No
primary antibody and IgG controls were included in every run
(see online supplementary ﬁgure S1). Consecutive sections were
tartrate resistant acid phosphatase (TRAP) stained33 (see online
supplementary methods).
Knee swelling
Rat knee diameters were measured (mean of three readings per
knee, Mitutoyo digital calliper, RS Components) and the differ-
ence between inﬂamed and contralateral knees presented.
IL-6 ELISA
Serum IL-6 concentrations were quantiﬁed from tail bleeds (six
AIA, six AIA+NBQX, days 0, 1, 2, 3, 7, 14 and 21) (IL-6
Quantikine ELISA, R&D Systems).
Footprint scoring
Following training, walking patterns were evaluated by hind-
footprint analysis (six AIA, six AIA+NBQX, three naive rats).34
Paws were dipped in paint prior to free movement along a
paper-lined walkway (1 m long, 10 cm wide). Three sets of six
sequential steps were recorded per rat per day. Limb rotation,
stride length and stance width were measured.34
Imaging
Whole rat knees (day 21) underwent X-ray and MRI. X-rays of
both knees (nine AIA, nine AIA+NBQX, three naive) were
obtained using a Kodak FX Pro In-vivo Imaging System
(Advanced Molecular Vision). For MRI, both knees (six AIA,
six AIA+NBQX) were imaged (Bruker Biospin Advance 9.4 T
(400 mHz) system, transmit-receive quadrature coil, RARE-MRI
sequence: TE=1250 ms, TR=24 ms, FA=180°, matrix
size=580×280×280, FOV=58×28×28 mm) and 3D datasets
manipulated to obtain representative mid-sagittal planes of each
knee (Analyze 10.0, Mayo Clinic, Rochester).
mRNA expression
Menisci, patella, femoral shaft (FS), femoral condyle (FC) and
tibial plateaux (TP) were dissected from both knees (six AIA, six
AIA+NBQX, day 21). Total RNA was extracted (TRIzol,
Invitrogen), DNase treated (DNA-free, Ambion), 300 ng reverse
transcribed (SuperScript III, Invitrogen; ribonuclease inhibitor
and random primers, Promega) and messenger RNA (mRNA)
expression quantiﬁed by RT-qPCR (SYBR Green JumpStart Taq
ReadyMix, Sigma; Stratagene MX3000P) using intron-spanning
primers (Primer 3) (see online supplementary table S5).20
Sequencing of cloned RT-PCR products conﬁrmed primer
speciﬁcity.
Standard curves for GluRs and IL-6 were generated from rat
brain and spleen cDNAs, respectively, to conﬁrm linearity
(R2≥0.95) and efﬁciency (90%–110%) for relative quantiﬁcation.35
Absolute RT-qPCR (see online supplementary table S5) quan-
tiﬁed osteoprotegerin (OPG), receptor activator of nuclear
factor κ-B ligand (RANKL), cathepsin K and collagen type I
alpha (COL1A1) mRNA in FC and TP using standard curves
(101–107 copies/μL) of RT-PCR products cloned in pGEM-T
(Promega).
NormFinder identiﬁed the optimal combinations of
reference genes (GAPDH, HPRT1, eEF2 and YWHAZ) for
normalisation.36
Osteoblast assays
The effects of NBQX (200 mM) on cell number and mineralisa-
tion of human primary osteoblasts (HOBs) from OA total knee
replacement bone (three patients) were assessed by an MTS
assay (Promega) (12 replicates/patient) and Alizarin Red S stain-
ing37 (20 days mineralising culture, four replicates/patient)
respectively (see online supplementary methods).
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Figure 1 Representative human OA sample showing α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 2 (AMPAR2) and KA1
immunohistochemistry in the medial tibial plateaux (MTP). (A), (C) and (D) are all images from the same location in the outer MTP. (A) Safranin-O
stain reveals the architecture of the bone and cartilage, with extensive bone remodelling (BR) and breaching (TMB) of the tidemark (TM), which is
almost completely lost. (B) Synovial tissue from the same patients showed evidence of inﬂammation indicated by perivascular lymphoid aggregates
(open arrow) and a thickened synovial lining (small arrow). (C) AMPAR2 was localised to areas of remodelling, particularly to the TMB regions
(arrows). (E) Osteocyte AMPAR2 staining was occasionally observed in small areas (arrow); however, many osteocytes remained negative (arrow
head). No AMPAR2 staining was seen in osteoclasts (arrow head (F)) or bone lining cells (arrow head (G)) from normal areas of bone. (D) KA1
localised to remodelling bone (arrows), osteoclasts (arrow (I)) and osteoblasts (arrow ( J)). No KA1 staining was seen in osteocytes (arrow head (H)).
(K, L) AMPAR2 stained chondrocytes (arrow (M)) near the ﬁbrillated cartilage surface down to the middle/deep zone interface, appearing strongest
in the middle zone, with no staining near the TM (indicated by arrows). (N, O) KA1 stained chondrocytes (arrow (P)) near the surface to the upper
middle zone, with no staining in the deep zone. Corresponding negative controls (no primary antibody) and rabbit IgG controls were negative for
KA1 and AMPAR2 (see online supplementary ﬁgure S1). Boxes indicate where higher power image was taken. Scale bars: (A–D), 200 μm; (E, G, J,
M, P), 50 μm; (F, H, I), 25 μm; (K, N), 500 μm; (L, O), 100 μm.
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Statistics
Using Minitab 16, data were tested for normality and equal var-
iances prior to ANOVA (histological inﬂammation (Fisher’s) and
COL1A1, RANKL, OPG mRNA expression (Tukey–Kramer)) or
general linear model two-way ANOVA (GluR mRNA expression
(Tukey–Kramer)) with individual post hoc tests. Two sample t
tests were used for cell number. Non-parametric data used
Kruskal–Wallis (footprints, histological joint degradation, IL-6
and cathepsin K mRNA expression) or Sheirer–Ray–Hare (knee
swelling, joint compartment degradation) with Mann–Whitney
post hoc tests. Means±SE of the mean (SEM) are presented.
RESULTS
GluRs are expressed in human arthritis
All patients showed cartilage ﬁbrillation, tidemark breaches and
proteoglycan loss, with OA MTP degradation scores ranging
from 9 to 13 (ﬁgure 1A, see online supplementary ﬁgure S2).
Synovial inﬂammation occurred in OA samples, with scores of
1–2 (ﬁgure 1B).
In OA, AMPAR2 localised to mononuclear cells (including
some osteocytes) in areas of bone remodelling (ﬁgure 1C,E),
but not osteoclasts (ﬁgure 1F). KA1 localised to remodelling
bone (ﬁgure 1D), osteoclasts (ﬁgure 1I) and osteoblasts (ﬁgure
1J) but not to osteocytes (ﬁgure 1H). Chondrocytes expressed
both receptors, with more staining near the cartilage surface
and none in the deep zone (ﬁgure 1K–P). AMPAR2 and KA1
immunopositive chondrocytes were abundant in the middle
section of MTP cartilage but less common in the severely
degraded outer MTP cartilage (see online supplementary ﬁgure
S2). AMPAR2 and KA1 staining in the bone localised mainly to
remodelling bone in the outer segment of the MTP (see
online supplementary ﬁgure S2). Similar patterns occurred in
RA, with KA1 and AMPAR2 present in osteoclasts (see online
supplementary ﬁgure S3).
AIA and NBQX inﬂuence GluR expression
KA1 and AMPAR2 proteins were expressed in chondrocytes
and synovial lining cells (not shown) in all rats, and localised to
remodelling bone in AIA and AIA+NBQX (ﬁgure 2).
Figure 2 KA1 and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 2 (AMPAR2) immunohistochemistry and tartrate resistant acid
phosphatase (TRAP) staining in the lateral femoral condyle of naive, antigen-induced arthritis (AIA) and AIA+NBQX rats. Chondrocytes in all animals
expressed KA1 and AMPAR2 (A–C, G–I, respectively, black arrows). Neither proteins localised to osteocytes or mononuclear bone cells (D, J, red
arrow heads) in naive rats; however, in AIA and AIA+NBQX rats, AMPAR2 was expressed in osteocytes, mainly in areas of bone remodelling (K, L,
red arrow). In AIA rats, mononuclear bone cells and areas of bone remodelling stained intensely for KA1 and AMPAR2 (B, E, H, K). AIA+NBQX rats
showed less bone remodelling and subsequently less staining of both proteins (C, F, I, L, black arrow heads). Abundant TRAP staining was found in
AIA rats (N) indicating the presence of more osteoclasts compared with naive (M) and AIA+NBQX rats (P). Consecutive sections showed expression
of KA1 (E) and AMPAR2 (K) in TRAP positive osteoclasts (O) in AIA rats (blue arrows). Black boxes are shown at ×40 in images underneath. (O) ×40
Image of boxed area in N. Corresponding negative controls (no primary antibody) and rabbit IgG controls were negative for KA1 and AMPAR2 (see
online supplementary ﬁgure S1). Scale bars: (A–C, G–I, M, N, P), 100 mm; (D–F, J–L, O), 50 mm.
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Osteocytes and other mononuclear cells in remodelling bone
expressed AMPAR2 in AIA and AIA+NBQX (ﬁgure 2K,L).
NBQX reduced the extent of remodelling, with an apparent
reduction of GluR positive cells (ﬁgure 2). Neither AMPAR2
nor KA1 localised to mononuclear bone cells in naive animals
(ﬁgure 2). TRAP positive osteoclasts in AIA coexpressed KA1
and AMPAR2 in consecutive sections (ﬁgure 2).
GluR transcripts (except GluR5 and NMDAR1) were
detected in all rat joint tissues (see online supplementary ﬁgure
S4). AIA and AIA+NBQX rats showed no differences in GluR
mRNA expression, except for a ﬁvefold increase in patella
AMPAR3 in AIA that remained at contralateral control levels in
AIA+NBQX (p<0.05, supplementary ﬁgure S4).
NBQX reduces inﬂammation and IL-6 expression
Peak knee swelling following arthritis induction (day 1, 4.4
±0.14 mm) was reduced in AIA+NBQX rats (2.95±0.23 mm,
33% reduction, p<0.001) and at all other time points
(p<0.001, ﬁgure 3A).
Serum IL-6 was undetectable in AIA samples (<21 pg/mL).
However, at day 21, a threefold increase in meniscal IL-6
mRNA in the inﬂamed knee of AIA rats compared with the
contralateral knee (p<0.05) remained at control levels in AIA
+NBQX (p<0.05, ﬁgure 3B). IL-6 mRNA was not detected in
FC, FS, TP and patella.
Synovial inﬂammation scores were reduced by NBQX treat-
ment (7.67±0.41 vs 5.11±0.65, p<0.001) (ﬁgure 3C). Naive
animals displayed normal synovial lining, 2–4 cells thick, with
underlying adipose tissue, whereas AIA induced synovial hyper-
plasia, exudate and inﬁltrate that were reduced by NBQX treat-
ment (ﬁgure 3D–L).
NBQX restores weight bearing
While AIA rats had no right hind-footprints on days 1 and 2
(ﬁgures 4A,B), NBQX restored weight bearing on these days,
comparable with naive rats. Walking abnormalities occurred in
AIA and AIA+NBQX rats, with greater foot rotation (ﬁgure 4B)
and stance width (ﬁgure 4C) and shorter stride length (ﬁgure
4D) than naive rats (p<0.05).
Figure 3 Swelling, synovial inﬂammation and IL-6 mRNA expression in knees from naive, antigen-induced arthritis (AIA) and AIA+NBQX rats
culled on day 21. (A) Signiﬁcantly less knee swelling was found in NBQX treated rats compared with AIA rats over 21 days (***p<0.001). (B)
Signiﬁcantly less IL-6 mRNA expression in the right inﬂamed knee was found in NBQX treated rats compared with AIA rats (*p<0.05). (C) NBQX
treated rats had a signiﬁcantly lower inﬂammation score compared with AIA rats (***p<0.001). (D) Naive animals had a normal synovial lining (SL)
(G) which was 2–4 cells thick with adipose tissue (Ad) directly beneath. The articular surface ( J) consisted of a layer of smooth cartilage (Ca) over
subchondral bone (Bo). (E, F) Synovial hyperplasia (pannus (P)), exudate (E), inﬂammatory cell inﬁltrate (ICI) and articular surface degradation
apparent in AIA rats (H, K) was less severe in AIA+NBQX rats (I, L). MTP, medial tibial plateaux; LTP, lateral tibial plateaux; MFC, medial femoral
condyle; LFC, lateral femoral condyle; M, meniscus. Boxes in (D–F) indicate where images in (G–L) are from. Scale bars: (D–F), 1 mm; (G–I), 50 mm;
( J–L), 100 mm.
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NBQX reduces joint degradation
NBQX treatment reduced cartilage and bone pathology (ﬁgure 5).
AIA caused loss of cartilage and substantial subchondral bone
remodelling, whereas NBQX treated knees resembled those from
naive rats, except for remodelling at the outer edges (ﬁgure 5A).
NBQX reduced AIA severity score (39.3±4.6) by 27% (28.8±1.7,
p<0.001) although not to naive values (11.7±2.7, p<0.001)
(ﬁgure 5B).
While severity scores did not vary signiﬁcantly across joint
quadrants (MTP, lateral TP, medial FC, lateral FC), scores were
lower in the whole FC following NBQX treatment (20.9±2.99
(AIA) to 12.7±0.85 (AIA+NBQX), p<0.01, ﬁgure 5C). NBQX
lowered each score component, showing the greatest effect in
bone (ﬁgure 5D, see online supplementary table S6). Severe
bone erosions and synovial inﬂammation in AIA revealed by
x-ray (ﬁgure 6A–C) and MRI (ﬁgure 6D–F) were attenuated by
NBQX treatment.
NBQX affects bone markers
Threefold increases in cathepsin K mRNA (pooled FC and TP)
in AIA compared with contralateral control knees (p<0.01) was
halved by NBQX (p<0.05), but not restored to control values
(p<0.05, ﬁgure 6G). COL1A1 expression was increased in AIA
(p<0.001) and AIA+NBQX (p<0.05) compared with contra-
lateral controls (ﬁgure 6H). Increased RANKL mRNA
expression (p<0.05) and RANKL to OPG ratios (p<0.01) in
AIA compared with contralateral controls were prevented by
NBQX treatment (ﬁgure 6I,K). Neither AIA nor AIA+NBQX
affected OPG mRNA expression (ﬁgure 6J).
NBQX reduces HOB number and mineralisation
NBQX treatment reduced HOB number at days 2 and 5
(p<0.001) and prevented mineralisation in all cultures (see
online supplementary ﬁgure S5).
DISCUSSION
To determine whether glutamatergic signalling inﬂuences local
inﬂammatory processes underlying arthritic pathologies, we
investigated synovial inﬂammation and AMPA/KA GluR expres-
sion in human OA, RA and rat AIA, and determined whether
AMPA/KA GluR antagonists affect AIA pathology. Characteristic
synovial inﬂammation occurred in all arthritis patients.30 38 39
AMPA and KA GluRs were expressed in inﬂamed synovium,
and diseased areas of bone and cartilage in human arthritic
tissue and rat AIA. A single intra-articular NBQX injection pro-
foundly reduced joint pathology in AIA, reducing knee swelling
by 33%, histological synovial inﬂammation scores by 34% and
degeneration scores by 27%. The protection offered by NBQX
exceeded that of etanercept, inﬂiximab and methotrexate in the
same model. A single intra-articular injection of methotrexate at
the time of induction did not reduce swelling or degeneration,
Figure 4 Footprint analysis of naive, antigen-induced arthritis (AIA) and AIA+NBQX rats. (A) Day 1 hindlimb footprints from the three
experimental groups. AIA rats often lacked a right footprint (circled) whereas AIA+NBQX rats displayed a gait pattern resembling that of naive
animals. Measurements of degree of foot rotation, stride length and stance width are indicated. (B–D) Analysis of foot rotation in the right inﬂamed
limb (B), stance width (C) and stride length (D). (B) AIA and AIA+NBQX rats have a signiﬁcantly greater degree of foot rotation in the right limb
compared with naive rats. On days 1 and 2, AIA rats were unable to weight bear and therefore lack data points. Stance width was increased (C) and
stride length decreased (D) in AIA and AIA+NBQX rats compared with naive. *p<0.05, **p<0.001 AIA+NBQX compared with naive; #p<0.05,
##p<0.001 AIA compared with naive.
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and although liposomally conjugated methotrexate reduced
knee swelling by 39% on day 1, long-term effects are unre-
ported.29 Six intraperitoneal injections of etanercept and inﬂixi-
mab had milder effects on swelling than NBQX (∼20%
reduction, days 1–7), and no effect on joint pathology at day 21
in rat AIA.40 Continuous administration of etanercept (intra-
thecal)41 and leﬂunomide (oral)42 was required to reduce joint
pathology in rat AIA. Thus, NBQX treatment in the AIA model
is more effective than equivalent administration of approved
drugs.
This is the ﬁrst report to demonstrate localisation of GluRs to
bone, cartilage and synovial cells in human OA and RA tissue.
This is particularly important for OA as it is a common disease,
with limited therapeutic options, where current trials are testing
efﬁcacy of anti-inﬂammatory treatments.43 44 In human OA and
RA, AMPAR2 localised to mononuclear bone cells, including
osteocytes, and KA1 to osteoclasts and osteoblasts but not osteo-
cytes in remodelling bone. Similarly, in rat AIA, mononuclear
cells and TRAP stained osteoclasts in remodelling bone
expressed AMPAR2 and KA1, consistent with the effects of
these iGluRs on osteoblast45 and osteoclast activities.46 NBQX
treatment in AIA reduced bone remodelling and therefore GluR
abundance. Rodent osteoblasts, osteocytes and osteoclasts
express AMPAR2 protein, and osteoblasts express KA1,16 but
there have been no reports in human bone cells. AMPAR2 was
not detected in osteocytes in naive animals, consistent with pre-
vious reports,46 but was expressed in AIA osteocytes.
AMPAR2 and KA1 were expressed by chondrocytes in naive,
AIA and AIA+NBQX rats, and in human OA and RA tissue,
where GluRs were abundant near the surface and towards the
mid-zone. Chondrocytes release glutamate and express AMPA47
and NMDA GluRs.18 NMDA GluR antagonists decrease prolif-
eration and inhibit IL-1β induced increases in cyclooxygenase-2,
IL-6 and MMP3 mRNA expression in chondrocytes.18
However, KA GluR expression and the role of AMPA/KA GluRs
have not been reported in chondrocytes.
Our observation that NBQX treatment reduced knee swelling
and synovial inﬂammation over 21 days is the ﬁrst to show an
effect of AMPA/KA GluR antagonists on swelling and long-lasting
anti-inﬂammatory effects of any GluR antagonist after a single
injection. A study targeting all iGluRs with a single intra-articular
injection in rat CFA arthritis only reported short-term reduction of
swelling.27 An NMDA GluR antagonist had long-term effects on
paw synovitis in mouse CIA, but this required 12-hourly, intra-
peritoneal injections.21 The anti-inﬂammatory effects of NBQX
may be mediated by IL-6.20 Although serum IL-6 concentrations
were too low to quantify,48 49 increased meniscal IL-6 mRNA
expression in AIA was reduced by NBQX treatment, suggesting
that bone, marrow and/or cartilage cells50 in the meniscus may
respond to glutamate to produce IL-6.51–53
NBQX treatment restored weight bearing over 2 days follow-
ing AIA induction, probably reﬂecting reduced pain.54 Previous
studies found that injection of MK801 (NMDAR antagonist) or
NBQX into the rat knee inhibits arthritis pain for 24 h,25 a
single intra-articular injection of combined NMDAR and
AMPA/KA GluR antagonists alleviates allodynia over 3 days27
and repeated injection of AMPA GluR antagonists (0–23 h) fol-
lowing CFA arthritis alleviates inﬂammatory pain.26 However,
Figure 5 Joint degradation and remodelling in naive, antigen-induced arthritis (AIA) and AIA+NBQX rats on day 21. (A) Representative toluidine
blue stains of the lateral femoral condyle. (A, B) AIA+NBQX rats displayed less severe cartilage and bone pathology scores compared with AIA rats
(p<0.001). (C) AIA+NBQX rats showed a signiﬁcantly lower joint severity score in the femoral condyle compared with AIA rats (p<0.001). Abundant
bone remodelling in AIA rats, indicated by toluidine blue staining (A), was signiﬁcantly reduced in AIA+NBQX rats (arrows, p<0.001) (A, D (BC
parameter)). (D) Chondrocyte appearance, proteoglycan loss and tidemark integrity scores were also lower in AIA+NBQX compared with AIA rats
(p<0.01). CSI, cartilage surface integrity; CA, chondrocyte appearance; PL, proteoglycan loss; TI, tidemark integrity; BC, bone changes. *p<0.05,
**p<0.01, ***p<0.001.
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our data are the ﬁrst to demonstrate 2-day restoration of joint
loading from a single intra-articular treatment of one GluR
antagonist. This body of evidence indicates that peripheral
inhibition of AMPA/KA GluRs reduces pain in arthritis.
This is the ﬁrst study to show that a single intra-articular
injection of any GluR antagonist alleviates cartilage and bone
destruction in arthritis. A single intra-articular injection of com-
bined iGluR antagonists did not affect cartilage erosion in CFA
arthritis.27 While memantine (NMDAR antagonist) alleviated
synovitis and joint pathology in CIA, continual 12-hourly intra-
peritoneal administration of the drug was necessary.21
Since AMPA/KA GluRs localised to remodelling bone in
human OA, RA and rat AIA, we quantiﬁed GluR and bone cell
mRNAs in joint tissues. Increased AMPAR3 mRNA expression
in AIA patella was restored to normal by NBQX, and coincided
with increased mRNAs reﬂecting osteoclast activation (RANKL),
bone resorption (Cathepsin K) and bone formation (COL1A1).
Cathepsin K and RANKL mRNA levels and RANKL to OPG
ratios were reduced by NBQX. AMPA increases bone formation
and mineralisation,45 whereas AMPAR antagonists reduce bone
mass,55 inhibiting osteoblast activity and mineralisation.45
Consistent with this, NBQX reduced cell number and prevented
mineralisation in HOBs from OA patients. Thus, the protective
effect of NBQX in AIA may reﬂect inhibition of osteoblast activ-
ity associated with reduced RANKL mediated activation of
osteoclasts. However, NBQX may also target AMPA and KA
GluRs expressed by synoviocytes56 and chondrocytes57 to regu-
late RANKL or directly inhibit osteoclast activity.46
In conclusion, a single intra-articular injection of NBQX alle-
viated inﬂammation, pain and joint degeneration in rat AIA. Thus,
AMPA/KA GluR antagonists have potential to alleviate multiple
symptoms in any form of arthritis where local inﬂammatory pro-
cesses are involved. GluR antagonists, tolerated in humans,58–60
and which do not cross the blood–brain barrier,58 61 are a timely
potential therapeutic for modulating glutamatergic signalling in
joints to treat arthritis.
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